Company intelligence / Profile preview

MirImmune

Cambridge, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

MirImmune generated preclinical proof-of-concept data showing that sd-rxRNA-treated immune cells (targeting immune checkpoints such as PD-1 and LAG-3) could enhance tumor cell killing in vitro and in vivo; CAR-T and TIL approaches in models demonstrated slowed tumor growth and melanoma cell eradication[3].

Therapeutic areas: Oncology
Modalities: RNA therapyCell therapyRNA interference therapy
Industry: Biotech

Partnerships

RXi Pharmaceuticals (licensing and acquisition partner)[3][5]

Beyond the preview

Go deeper on MirImmune.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MirImmune.

Explore the full profile